Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.

Hannes SallmonTünay AydinStefanie HortAnja KubinskiChristina BodeTamara KlippsteinStefanie EndesfelderChristoph BührerPetra Koehne

Published in: Cardiology in the young (2019)

Our results indicate that there is no association between vascular endothelial growth factor polymorphism rs2010963 status and the occurrence of patent ductus arteriosus or the response to cyclooxygenase inhibitor treatment in a large cohort of preterm infants. Additional studies are needed to determine the role of genetic factors on patent ductus arteriosus incidence and treatment response.

Keyphrases

vascular endothelial growth factor
preterm infants
endothelial cells
low birth weight
risk factors
risk assessment
gene expression
nitric oxide synthase
replacement therapy
copy number